Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the start of a phase 1b/2a clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular edema (DME).
https://breye.com/wp-content/uploads/2023/01/Breye-Logo.jpg00bryteyeshttps://breye.com/wp-content/uploads/2023/01/Breye-Logo.jpgbryteyes2024-01-25 08:30:582024-01-25 08:31:29Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
Golgi Neurosciences S.r.l., the biotech incubator dedicated to the development of new treatments for devastating diseases, and Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases, today announces a collaboration to develop the P2X7 receptor antagonist programme.
https://breye.com/wp-content/uploads/2023/01/Breye-Logo.jpg00bryteyeshttps://breye.com/wp-content/uploads/2023/01/Breye-Logo.jpgbryteyes2023-07-25 08:00:022023-07-25 08:00:02Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer
Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the appointment of Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors.
https://breye.com/wp-content/uploads/2023/01/Breye-Logo.jpg00bryteyeshttps://breye.com/wp-content/uploads/2023/01/Breye-Logo.jpgbryteyes2023-04-20 08:30:052023-04-20 08:33:36Breye Therapeutics Strengthens Management Team and Board
Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the start of a phase 1b/2a clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular edema (DME).
Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer
Golgi Neurosciences S.r.l., the biotech incubator dedicated to the development of new treatments for devastating diseases, and Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases, today announces a collaboration to develop the P2X7 receptor antagonist programme.
Breye Therapeutics Strengthens Management Team and Board
Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the appointment of Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors.